SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.

Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti-leukaemic treatment, developed COVID-19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti-CD20 or venetoclax therapy, correlating with perivaccine B-cell count. Vaccination appeared to protect from severe COVID-19 in 11 patients with breakthrough infection. © 2022 British Society for Haematology and John Wiley & Sons Ltd.

Citation

Enrico Tiacci, Alessandro Mancini, Monia Marchetti, Gianna Maria D'Elia, Anna Candoni, Alessandro Morotti, Alessandra Romano, Alessandro Gozzetti, Alessandro Broccoli, Luca De Carolis, Riccardo Bruna, Maria Chiara Tisi, Carmine Selleri, Monia Capponi, Daniele Vallisa, Chiara Cattaneo, Matteo Giovanni Della Porta, Alessandro Busca, Brunangelo Falini, Massimo Massaia, Lorenza Bertù, Alessandro Pulsoni, Paolo Rivela, Paolo Corradini, Francesco Passamonti. SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia. British journal of haematology. 2023 May;201(3):411-416

Mesh Tags

Substances

PMID: 36541031

search → result